Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients
- 1 January 2008
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (4), 769-778
- https://doi.org/10.1080/10428190701843213
Abstract
From 1996 to April 2006, 174 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin lymphoma (HL) received ESHAP as salvage and for mobilisation. Males 92, females 76. DLCL 64: HL 104, prior radiation in 35%. First relapse 45%, second relapse 12%, induction failure 43%. Median prior chemotherapy cycles were 6. Median age at apheresis was 26.5 years. Six patients failed mobilisation and 21 patients had CD34+ cells collection < 2 x 10(6)/kg on first apheresis. Median CD34+ cells/kg collection was 5.5 x 10(6)/kg for first apheresis and 6.7 x 10(6)/kg for all apheresis. We evaluated impact of histology, gender, age, stage, marrow involvement, prior radiation and chemotherapy cycles, timing (relapse1: relapse > 1: refractory), platelet count and weight. For first apheresis collection; all patients, younger age (p = 0.004), for DLCL (64), younger age (p = 0.021) and higher platelet count (p = 0.013) and for HL (104), younger age (p = 0.036) and male gender had better CD34+ cells collection. For all apheresis product, for all patients, age (p = 0.001) and no prior radiation therapy (p = 0.051) had better CD34+ cells collection. Higher first harvest CD34+ cells collection also resulted in early neutrophil (p < or = 0.001) and platelet (p = 0.004) engraftment.Keywords
This publication has 23 references indexed in Scilit:
- Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignanciesClinical and Laboratory Haematology, 2008
- ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patientsBone Marrow Transplantation, 2006
- ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSFBone Marrow Transplantation, 2005
- Collection of peripheral blood progenitor cells: analysis of factors predicting the yieldsTransfusion and Apheresis Science, 2003
- Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphomaBone Marrow Transplantation, 2002
- Harvesting of Autologous Blood Stem Cells after a Mobilising Regimen with Low-dose CyclophosphamideLeukemia & Lymphoma, 2002
- Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphomaBone Marrow Transplantation, 2001
- Is There Any Difference in PBPC Mobilization Between Cyclophosphamide Plus G-CSF and G-CSF Alone in Patients with Non-Hodgkin's Lymphoma?Leukemia & Lymphoma, 2000
- Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring systemBone Marrow Transplantation, 1998
- The COBE Spectra cell separator is more effective than the Haemonetics MCS-3P cell separator for peripheral blood progenitor cell harvest after mobilization with cyclophosphamide and filgrastimTransfusion, 1997